Skip to content

Janux Therapeutics JANX Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$37.8M+24.8%
Xencor logo
XencorXNCR
$4.03M+10.8%
Vor Biopharma logo
Vor BiopharmaVOR
$307K-92.8%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$725K-46.2%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$22.53M+3.2%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$13M+8.3%

Other financials

Income statement

See full
Revenue$3.7M
Operating income-$34.2M+2.0%
Net income-$24.4M-3.6%
EPS (diluted)-$0.39-2.6%

Balance sheet

See full
Cash & equivalents$51.8M-29.7%
Total debt$21.6M-4.6%
Total equity$941.5M-7.0%
Total assets$1.0B-2.1%

Cash flow

See full
Operating cash flow-$12.3M+27.5%
CapEx$273.0K-26.4%
Free cash flow-$12.6M+27.5%

Valuation

See full
Market cap$889.15M-36.3%
Enterprise value$858.89M-36.2%
P/S64.8×-84.8×

Profitability

See full
Operating margin-1,143.1%-65.1pp
Net margin-833.6%+0.9pp
FCF margin-571.6%+98.3pp

Returns & leverage

See full
Return on equity-11.7%+4.1pp
Debt / equity0.0×
Current ratio17×-41.5×

Where this comes from

Reported directly by Janux Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Janux Therapeutics's operating lease liabilities (current)?
Janux Therapeutics (JANX) reported operating lease liabilities (current) of $2.47M in Q1 2026.
How has Janux Therapeutics's operating lease liabilities (current) changed year-over-year?
Janux Therapeutics's operating lease liabilities (current) increased by 36.5% year-over-year, from $1.81M to $2.47M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.